Cyclo Therapeutics to Present at 8th Annual Dawson James Conference
05 Outubro 2023 - 9:05AM
Business Wire
Live webcast presentation on Thursday, October
12th at 12:00 PM ET
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or
the “Company”), a clinical stage biotechnology company dedicated to
developing life-changing medicines through science and innovation
for patients and families living with diseases, today announced
that N. Scott Fine, Chief Executive Officer and Joshua Fine, Chief
Financial Officer of Cyclo Therapeutics will present at the 8th
Annual Dawson James Conference being held in Jupiter, FL on
Thursday, October 12, 2023 at 12:00 PM ET.
In addition to the panel presentation, management will be
available to participate in in-person one-on-one meetings with
qualified members of the investor community who are registered to
attend the conference. For more information about the conference,
please visit the conference website.
A live webcast of the presentation will be available on the
Events page of the Investors section of the Company’s website
(cyclotherapeutics.com). A webcast replay will be available two
hours following the live presentation and will be accessible for 90
days.
About Cyclo Therapeutics Cyclo Therapeutics, Inc. is a
clinical-stage biotechnology company dedicated to developing
life-changing medicines through science and innovation for patients
and families living with disease. The Company’s Trappsol® Cyclo™,
an orphan drug designated product in the United States and Europe,
is the subject of four formal clinical trials for Niemann-Pick
Disease Type C, a rare and fatal genetic disease,
(www.ClinicalTrials.gov NCT02939547, NCT02912793, NCT03893071 and
NCT04860960). The Company is conducting a Phase 2b clinical trial
using Trappsol® Cyclo™ intravenously in early Alzheimer’s disease
(NCT05607615) based on encouraging data from an Expanded Access
program for Alzheimer’s disease (NCT03624842). Additional
indications for the active ingredient in Trappsol® Cyclo™ are in
development. For additional information, visit the Company’s
website: www.cyclotherapeutics.com.
About Dawson James Dawson James Securities specializes in
capital raising for small and microcap public and private growth
companies primarily in the Life Science/Health Care, Technology,
Clean tech, and Consumer sectors. We are a full-service investment
banking firm with research, institutional and retail sales, and
execution trading and corporate services. By investing the time
required to completely understand your business, we can provide an
appropriate capital transaction structure and strategy including
direct investment through our independent fund. Our team will
assist in crafting your vision and shaping your message for the
capital markets. Headquartered in Boca Raton, FL, Dawson James is
privately held with offices in New York, Maryland, and New Jersey.
www.dawsonjames.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231005589716/en/
Investor Contact: JTC Team, LLC Jenene Thomas (833)
475-8247 CYTH@jtcir.com
Cyclo Therapeutics (NASDAQ:CYTH)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Cyclo Therapeutics (NASDAQ:CYTH)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024